Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL-21Generic

TRI-LEGEST 21

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Standard Dose
0.02MG,0.03MG,0.035MG;1MG,1MG,1MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview TRI-LEGEST 21 is listed in Drugs@FDA under application 076405 (ANDA).

Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE ACETATE Form and strength TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG Sponsor BARR Submission history Latest submission status date: 2007-10-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview TRI-LEGEST 21 is listed in Drugs@FDA under application 076405 (ANDA). Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORETHINDRONE ACETATE Form and strength TABLET;ORAL-21 - 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG Sponsor BARR Submission history Latest submission status date: 2007-10-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
TRI-LEGEST 21 (ETHINYL ESTRADIOL; NORETHINDRONE ACETATE) | Drug Monograph | MedicHelpline